PRZEGLĄD AKTUALNYCH WYTYCZNYCH I BADAŃ ZASTOSOWANIA  KWASU ACETYLOSALICYLOWEGO W PREWENCJI PIERWOTNEJ  INCYDENTÓW SERCOWO-NACZYNIOWYCH

Tomasz Kordowski; Tomasz Tatara; Adam Fronczak

doi:10.56782/pps.29

Published : 2019-08-07

Vol. 17 No. 4 (2019)

REVIEW OF CURRENT GUIDELINES AND STUDIES ON USE OF ACETYLSALICYLIC ACID IN THE PRIMARY CARDIOVASCULAR EVENTS PREVENTION

Tomasz Kordowski

Tomasz Tatara

Adam Fronczak

DOI: https://doi.org/10.56782/pps.29

Abstract

Acetylsalicylic acid is a medicinal substance common use in medicine. The property of inhibiting platelet aggregation is widely used in the prevention of cardiovascular diseases. The role of acetylsalicylic acid is well established in the prevention of secondary cardiovascular events, while in the primary prevention of cardiovascular events, the opinions of researchers and cardiology association are divided. In the presented studies, acetylsalicylic acid reduced the risk of cardiovascular episodes, however, the risk of bleeding was often greater than the benefits of aspirin in primary prevention. There are many acetylsalicylic acid products available on the market. In order to minimize the risk of local irritation in the gastrointestinal tract, the use of film-coated formulations should be considered. The combination of acetylsalicylic acid and glycine seems promising, which increases the solubility of acetylsalicylic acid and has protective properties.

Keywords:

acetylsalicylic acid, prevention, cardiovascular events, glycine

Most read articles by the same author(s)

Wojciech Wahl, Dorota Jędrzejczyk-Okońska, Adam Fronczak, TOBACCO SMOKING EPIDEMIOLOGY AND EFFECTIVE NICOTINE ADDICTION CESSATION METHODS , Prospects in Pharmaceutical Sciences: Vol. 17 No. 5 (2019)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Kordowski, T., Tatara, T., & Fronczak, A. (2019). REVIEW OF CURRENT GUIDELINES AND STUDIES ON USE OF ACETYLSALICYLIC ACID IN THE PRIMARY CARDIOVASCULAR EVENTS PREVENTION. Prospects in Pharmaceutical Sciences, 17(4), 20–23. https://doi.org/10.56782/pps.29

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231, 232–235. DOI: https://doi.org/10.1038/newbio231232a0

Grześk G, Koziński M, Navarese EP, Kubica A, Grześk E, Kubica J, Zieliński M. Kwas acetylosalicylowy – podstawa leczenia przeciwpłytkowego. Folia Cardiologica Excerpta. 2011, 6, 1, 49-61.

Vane JR, Botting RM. Mechanism of Action of Aspirin-Like drugs. Semin Arthritis Rheum. 1997, 6 Suppl 1, 2-10. DOI: https://doi.org/10.1016/S0049-0172(97)80046-7

Czyż M, Watała C. Aspirin – the prodigious panacea? Molecular mechanisms of the action of acetylsalicylic acid in the organism. Postepy Hig Med. Dosw. 2005, 59, 105-15.

Kubica J, Koziński M, Grześk G. Mechanizmy działania leków przeciwpłytkowych. Folia Cardiologica Excerpta. 2009, 4, 1, 10-17.

Piepoli MF, Hoes AW, Agewall S et al. Wytyczne ESC dotyczące prewencji chorób układu sercowo-naczyniowego w praktyce klinicznej w 2016 roku. Kardiologia Polska. 2016, 74, 9, 821–936.

Baigent C, Blackwell L et al. Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009, 373, 1849–1860. DOI: https://doi.org/10.1016/S0140-6736(09)60503-1

Arnett DK et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019, 19, S0735- 1097. DOI: https://doi.org/10.1001/jamacardio.2019.2604

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018, 392, 1036– 1046. DOI: https://doi.org/10.1016/S0140-6736(18)31924-X

ASCEND Study Collaborative Group, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N. Engl. J. Med. 2018, 379,16, 1529-1539. DOI: https://doi.org/10.1056/NEJMoa1804988

McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N. Engl. J. Med. 2018, 379, 16, 1509–1518. DOI: https://doi.org/10.1056/NEJMoa1805819

Kasprzak M, Koziński M, Kubica A, Navarese EP, Grześk G, Kubica J. An overview of methods dedicated to protection of the digestive tract in patients treated with aspirin. Focus on clinical effectiveness and antiplatelet properties. Kardiologia Polska. 2012, 70, 4, 405–413.

http://pub.rejestrymedyczne.csioz.gov.pl/ [Data dostępu: 23.03.2019 r.].

Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991, 32, 77–83. DOI: https://doi.org/10.1111/j.1365-2125.1991.tb05616.x

Cox D, Maree AO, Dooley M, et al. Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke. 2006, 37, 8, 2153-8. DOI: https://doi.org/10.1161/01.STR.0000231683.43347.ec

Murtaza G, Karim S, Najam-ul-Haq M, Ahmad M, Ismail T, Khan SA, Bin AM, Hussain I. Interaction analysis of aspirin with selective amino acids. Acta Pol. Pharm. 2014, 71, 139-143.

Kusche W, Paxinos R, Haselmann J, Schwantes U, Breddin HK. Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy. Adv. Ther. 2003, 20, 237–245. DOI: https://doi.org/10.1007/BF02849852

Müller P, Dammann HG, Bergdolt H, Simon B. The effect of glycine on the gastroduodenal tolerability of acetylsalicylic acid. An endoscopic, controlled double-blind study in healthy subjects.

Arzneimittelforschung. 1991, 41, 812–814. DOI: https://doi.org/10.1212/WNL.41.6.812

Tomasz Kordowski

t-kordowski@wp.pl

Affiliation:

Aflofarm Farmacja Polska Sp. z o.o., ul. Partyzancka 133/151, 95-200 Pabianice Poland

Bio Statement (e.g., department and rank)

autor korespondujący, tel.: +48 509 470 019, e-mail: t-kordowski@wp.pl

Tomasz Tatara

Affiliation:

Zakład Zdrowia Publicznego Warszawskiego Uniwersytetu Medycznego, Wydział Nauki o Zdrowiu, Warszawski Uniwersytet Medyczny, ul. Jana Nielubowicza 5, Blok F, 02-097 Warszawa Poland

Adam Fronczak

Affiliation:

Zakład Zdrowia Publicznego Warszawskiego Uniwersytetu Medycznego, Wydział Nauki o Zdrowiu, Warszawski Uniwersytet Medyczny, ul. Jana Nielubowicza 5, Blok F, 02-097 Warszawa Poland